Tango Therapeutics (NASDAQ:TNGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Posted by Francis Steltz on Nov 10th, 2026

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) had its price objective lifted by JPMorgan Chase & Co. from $46.00 to $47.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 100.29% from the company’s previous close.

A number of other research firms have also issued reports on TNGX. Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a report on Friday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Tango Therapeutics in a report on Wednesday, November 4th. Mizuho upped their price target on shares of Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, July 17th. HC Wainwright lowered their price objective on shares of Tango Therapeutics from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Guggenheim boosted their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tango Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.54.

Get Our Latest Stock Analysis on TNGX

Tango Therapeutics Price Performance

Shares of NASDAQ:TNGX traded up $0.73 during trading on Tuesday, reaching $23.47. 1,627,293 shares of the company’s stock traded hands, compared to its average volume of 3,479,728. The company has a 50 day moving average of $23.32 and a 200-day moving average of $22.53. The stock has a market capitalization of $3.96 billion, a P/E ratio of -27.74 and a beta of 1.26. Tango Therapeutics has a 12 month low of $7.49 and a 12 month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Equities research analysts predict that Tango Therapeutics will post -1.41 earnings per share for the current fiscal year.

Insider Activity at Tango Therapeutics

In related news, insider Jessica Newcomb sold 8,200 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the sale, the insider owned 59,121 shares in the company, valued at approximately $1,431,910.62. This trade represents a 12.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at $2,832,231.21. The trade was a 18.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 47,231 shares of company stock worth $1,129,029. Corporate insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TNGX. TRV GP IV LLC bought a new position in Tango Therapeutics during the second quarter worth about $120,181,383,000. Tidal Investments LLC acquired a new position in Tango Therapeutics in the second quarter valued at about $1,731,000. Handelsbanken Fonder AB acquired a new position in Tango Therapeutics in the second quarter valued at about $9,000,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Tango Therapeutics in the second quarter worth about $19,884,000. Finally, Tema ETFs LLC bought a new stake in shares of Tango Therapeutics in the second quarter worth about $1,731,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells.

Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

Founded in 2017, Tango was established to apply advances in cancer genetics and functional genomics to drug discovery.